| Literature DB >> 32130166 |
Jeremy Hill1, Jourdan McGinn2, John Cairns2, Caroline Free3, Chris Smith4,5.
Abstract
BACKGROUND: Despite progress over the last decade, there is a continuing unmet need for contraception in Cambodia. Interventions delivered by mobile phone could help increase uptake and continuation of contraception, particularly among hard-to-reach populations, by providing interactive personalized support inexpensively wherever the person is located and whenever needed.Entities:
Keywords: Cambodia; contraception; cost-effectiveness; digital health; mHealth; postabortion contraception; postabortion family planning
Mesh:
Year: 2020 PMID: 32130166 PMCID: PMC7064963 DOI: 10.2196/16276
Source DB: PubMed Journal: JMIR Mhealth Uhealth ISSN: 2291-5222 Impact factor: 4.773
Figure 1Conceptual framework for the service provision model based on the MOTIF trial. Inputs from the MOTIF trial are shown in green. Models used to derive costs and effects are shown in yellow. IUD: intrauterine device; MOTIF: MObile Technology for Improved Family planning; OCP: oral contraceptive pill.
Service provision model parameters.
|
| Base | Deterministic range (95% CI) | Probabilistic distribution | ||||
|
|
|
|
| ||||
|
|
|
|
| ||||
|
| Oral contraceptive pill | 2172 | 2013-2330 | Lognormal | |||
|
| Injectable | 558 | 512-604 | Lognormal | |||
|
| Implant | 172 | 123-220 | Lognormal | |||
|
| IUDb | 112 | 72-153 | Lognormal | |||
|
|
|
|
| ||||
|
| Repeat abortion | 47 | 21-91 | Beta | |||
|
|
|
|
| ||||
|
|
|
|
| ||||
|
| Oral contraceptive pill | 3308 | 3112-3499 | Lognormal | |||
|
| Injectable | 325 | 291-358 | Lognormal | |||
|
| Implant | 75 | 42-109 | Lognormal | |||
|
| IUD | 63 | 32-93 | Lognormal | |||
|
|
|
|
| ||||
|
| Repeat abortion | 69 | 35-120 | Beta | |||
aPer 1000 participants per year.
bIUD: intrauterine device.
Figure 2Marie Stopes International Impact2 model framework. Inputs, outputs, and processes used in the Impact2 model are illustrated, as they apply to this study. Green: inputs to the model from the MOTIF trial. Yellow: effects reported in this study. Adapted from Weinberger et al [21]. CYPs: couple-years of protection; DALYs: disability-adjusted life-years; LAM: long-acting method; MOTIF: MObile Technology for Improved Family planning.
Unit costs.
|
| Base | Deterministic rangea | Probabilistic distribution | Comment/source | ||
|
|
|
|
|
| ||
|
|
|
| ||||
|
| Airtime: voice messages | 0.79 | 0.39-1.18 | Gamma | Actual costs from the MOTIF study | |
|
| Airtime: outgoing phone calls | 2.16 | 1.08-3.25 | Gamma | Actual costs from the MOTIF study | |
|
| Computer | 1.34 | 0.67-2.01 | Gamma | Actual costs from the MOTIF study | |
|
| Phone | 0.2 | 0.1-0.3 | Gamma | Actual costs from the MOTIF study | |
|
|
|
| ||||
|
| Oral contraceptive pill (one cycle) | 0.29 | 0.15-0.44 | Gamma | Direct cost reported by an MSICe clinic | |
|
| IUDd | 0.4 | 0.2-0.6 | Gamma | Direct cost reported by an MSIC clinic | |
|
| Medical abortion (Mariprist) | 0.7 | 0.35-1.05 | Gamma | Direct cost reported by an MSIC clinic | |
|
| Surgical abortion | 5 | 2.5-7.5 | Gamma | Personal communication with MOTIF trial authors | |
|
| Injectable contraceptive (one dose) | 0.5 | 0.25-0.75 | Gamma | Direct cost reported by an MSIC clinic | |
|
| Implanted subdermal contraceptive (Femplant) | 8 | 4-12 | Gamma | Direct cost reported by an MSIC clinic | |
|
| Long-acting contraceptive device removal | 3 | 1.5-4.5 | Gamma | Personal communication with MOTIF trial authors | |
|
|
|
|
|
| ||
|
| Midwife/health care service provider | 2.36 | 1.18-3.54 | Gamma | Direct cost reported by an MSIC clinic | |
|
| Counsellor | 2.52 | 1.26-3.78 | Gamma | Direct cost reported by an MSIC clinic | |
|
|
|
| ||||
|
|
|
|
|
| ||
|
| IUDd insertion | 5 | 2.5-7.5 | Gamma | Direct price to users reported by an MSIC clinic | |
|
| Implant insertion | 25 | 12.5-37.5 | Gamma | Direct price to users reported by an MSIC clinic | |
|
| Injectable (MSIC clinic) | 1 | 0.5-1.5 | Gamma | Direct price to users reported by an MSIC clinic | |
|
| Injectable (pharmacy) | 0.73 | 0.37-1.1 | Gamma | Direct price to users reported by a local pharmacy | |
|
| Oral contraceptive pill (MSIC clinic) | 0.4 | 0.2-0.6 | Gamma | Direct price to users reported by an MSIC clinic | |
|
| Oral contraceptive pill (pharmacy) | 0.37 | 0.19-0.56 | Gamma | Direct price to users reported by a local pharmacy | |
|
| IUD removal | 2 | 1-3 | Gamma | Direct price to users reported by an MSIC clinic | |
|
| Implant removal | 3.75 | 1.8-5.63 | Gamma | Direct price to users reported by an MSIC clinic | |
|
| Repeat abortion (surgical) | 25 | 12.5-37.5 | Gamma | Direct price to users reported by an MSIC clinic | |
|
| Repeat abortion (medical) | 20 | 10-30 | Gamma | Direct price to users reported by an MSIC clinic | |
|
|
|
| ||||
|
| Airtime to call a clinic/hotline (per min) | 0.07 | 0.04-0.11 | Gamma | Advertised cross-network charge in Cambodia | |
|
|
|
|
|
| ||
|
| Motorbike travel (per km) | 0.22 | 0.11-0.33 | Gamma | Data from Rozemuller et al [ | |
|
| Average distance from clinic to home (km) | 38.2 | 30.1-46.3f | Gamma | Data from the MOTIF study | |
|
|
|
|
|
| ||
|
| Gross national income per capita | 2534 | 2280.6-2787.4g | Gamma | World Bank development data [ | |
|
| Gross daily income per capita | 6.9 | 6.2-7.6g | Gamma | World Bank development data [ | |
|
| Repeat abortion (total household indirect cost) | 5.07 | 2.54-7.61 | Gamma | Data from Potdar et al [ | |
aThe range used for deterministic analysis was 50% above and below the base case estimate unless otherwise indicated. This range was then assumed to represent the 95% confidence interval of the distribution indicated for probabilistic sensitivity analysis.
bUnit costs were combined to calculate the service level costs used in the model.
cMOTIF: MObile Technology for Improved Family planning.
dIUD: intrauterine device.
eMSIC: Marie Stopes International Cambodia.
fRange used is the 95% confidence interval from MOTIF data.
gRange used is 10% above and below the base case estimate.
Base case cost and effect results for the MOTIF (MObile Technology for Improved Family planning) intervention versus standard of care.
|
| Intervention | Standard care | Incremental value | |
|
| ||||
|
| Provider | 4079.74 | −1625.20 | 5704.94 |
|
| User | 15,906.83 | 13,451.28 | 2455.55 |
|
| Total | 19,986.56 | 11,826.07 | 8160.49 |
|
| ||||
|
| Couple-years of protection | 1350.6 | 832.6 | 518.0 |
|
| Pregnancies avertedb | 441 | 260 | 180 |
|
| Abortions avertedb | 251 | 148 | 103 |
|
| U5c mortalities avertedb | 3 | 2 | 1 |
|
| Maternal mortalities avertedb | 0 | 0 | 0 |
|
| DALYsd averted | 241.6 | 142.8 | 98.8 |
aCosts and effects are calculated per 1000 users.
bRounded to the nearest whole.
cU5: under five.
dDALYs: disability-adjusted life-years.
Base case incremental cost-effectiveness ratio (ICER) results for the MOTIF (MObile Technology for Improved Family planning) intervention.
| Effect | ICER (US $ per unit of effect) |
| Couple-years of protection | 15.75 |
| Pregnancies averted | 45.22 |
| Abortions averted | 79.33 |
| U5a mortalities averted | 7659.96 |
| Maternal mortalities averted | —b |
| DALYsc averted | 82.57 |
aU5: under five.
bNo maternal mortalities were estimated to have been averted in either arm; therefore, no ICER calculation is possible.
cDALYs: disability-adjusted life-years.
Figure 3Tornado plot of deterministic sensitivity analysis using MOTIF intervention model parameters. For each parameter, the ICER was recalculated taking the upper and then lower deterministic range value. ICER ranges are centered on the ICER point estimate of US $82.57 per DALY averted. DALYs: disability-adjusted life-years; ICER: incremental cost-effectiveness ratio; IUD: intrauterine device; MOTIF: MObile Technology for Improved Family planning; MSIC: Marie Stopes International Cambodia; OC: oral contraceptive.
Figure 4Monte-Carlo simulation results plotted on the cost-effectiveness plane, with effects measured in DALYs averted. Linear demarcations of the upper and lower bounds for the cost-effectiveness threshold for DALYs averted are included for comparison. DALYs: disability-adjusted life-years; MOTIF: MObile Technology for Improved Family planning.
Figure 5Monte-Carlo simulation results plotted on the cost-effectiveness plane, with effects measured in CYPs. CYPs: couple-years of protection.
Figure 6Cost-effectiveness acceptability curve derived from Monte-Carlo simulations of MOTIF intervention results, with effects measured in DALYs averted. DALYs: disability-adjusted life-years; MOTIF: MObile Technology for Improved Family planning.
Figure 7Cost-effectiveness acceptability curve derived from Monte-Carlo simulations of MOTIF intervention results, with effects measured in CYPs averted. CYPs: couple-years of protection; MOTIF: MObile Technology for Improved Family planning.
Costs for users and providers in scenarios involving variable user fees.
|
| Base case | Scenario 1 (50% user fees) | Scenario 2 (no user fees) | Societal perspectivea | |
|
| |||||
| Intervention | 15,906.83 | 12,339.41 | 8772.00 | 19,986.56 | |
| Standard care | 13,451.28c | 10,864.97 | 8278.66 | 11,826.07 | |
| Incremental | 2455.55 | 1474.44 | 493.34 | 8160.49 | |
|
| |||||
| Couple-years of protection | 11.01 | 12.91 | 14.80 | 15.75 | |
| Pregnancies averted | 31.61 | 37.05 | 42.49 | 45.22 | |
| Abortions averted | 55.46 | 65.00 | 74.54 | 79.33 | |
| U5e mortalities averted | 5355.02 | 6275.95 | 7196.88 | 7659.96 | |
| Maternal mortalities averted | —f | — | — | — | |
| DALYsg averted | 57.72 | 67.65 | 77.58 | 82.57 | |
aCosts and ICERs from a societal perspective are included for reference. These results remain constant in each scenario, as the user fee represents a transfer from users to providers, but a net zero change from a societal perspective.
bResults are presented as total cost (direct and indirect) from a user perspective and ICER from a provider perspective to reflect the outcome of interest for the respective groups. Changes in demand resultant from the imposition of user fees have not been modelled as part of the scenario analysis.
cUnder standard care with 100% user fees, the program provides income to providers.
dICER: incremental cost-effectiveness ratio.
eU5: under five.
fNo maternal mortalities were estimated to have been averted in either arm; therefore, no ICER calculation is possible.
gDALYs: disability-adjusted life-years.